Stage-specific treatment of colorectal cancer: A microRNA-nanocomposite approach

Fadaka, Adewale Oluwaseun; Akinsoji, Taiwo; Klein, Ashwil; Madiehe, Abram Madimabe; Meyer, Mervin; Keyster, Marshall; Sikhwivhilu, Lucky Mashudu; Sibuyi, Nicole Remaliah Samantha

doi:10.1016/j.jpha.2023.07.008

Cited by 4 publications

(1 citation statement)

References 177 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRC is usually diagnosed at an advanced stage, which lowers cure rates and long-term survival [ 49 ]. Therefore, exploration of potential biomarkers for the early diagnosis of CRC is necessary.…”

Section: Discussionmentioning

confidence: 99%

UHPLC-HRMS-based Multiomics to Explore the Potential Mechanisms and Biomarkers for Colorectal Cancer

Wang,

Guan,

Tong

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Understanding the metabolic changes in colorectal cancer (CRC) and exploring potential diagnostic biomarkers is crucial for elucidating its pathogenesis and reducing mortality. Cancer cells are typically derived from cancer tissues and can be easily obtained and cultured. Systematic studies on CRC cells at different stages are still lacking. Additionally, there is a need to validate our previous findings from human serum. Methods Ultrahigh-performance liquid chromatography tandem high-resolution mass spectrometry (UHPLC-HRMS)-based metabolomics and lipidomics were employed to comprehensively measure metabolites and lipids in CRC cells at four different stages and serum samples from normal control (NR) and CRC subjects. Univariate and multivariate statistical analyses were applied to select the differential metabolites and lipids between groups. Biomarkers with good diagnostic efficacy for CRC that existed in both cells and serum were screened by the receiver operating characteristic curve (ROC) analysis. Furthermore, potential biomarkers were validated using metabolite standards. Results Metabolite and lipid profiles differed significantly among CRC cells at stages A, B, C, and D. Dysregulation of glycerophospholipid (GPL), fatty acid (FA), and amino acid (AA) metabolism played a crucial role in the CRC progression, particularly GPL metabolism dominated by phosphatidylcholine (PC). A total of 46 differential metabolites and 29 differential lipids common to the four stages of CRC cells were discovered. Eight metabolites showed the same trends in CRC cells and serum from CRC patients compared to the control groups. Among them, palmitoylcarnitine and sphingosine could serve as potential biomarkers with the values of area under the curve (AUC) more than 0.80 in the serum and cells. Their panel exhibited excellent performance in discriminating CRC cells at different stages from normal cells (AUC = 1.00). Conclusions To our knowledge, this is the first research to attempt to validate the results of metabolism studies of serum from CRC patients using cell models. The metabolic disorders of PC, FA, and AA were closely related to the tumorigenesis of CRC, with PC being the more critical factor. The panel composed of palmitoylcarnitine and sphingosine may act as a potential biomarker for the diagnosis of CRC, aiding in its prevention.

show abstract

Section: Discussionmentioning

confidence: 99%

UHPLC-HRMS-based Multiomics to Explore the Potential Mechanisms and Biomarkers for Colorectal Cancer

Wang,

Guan,

Tong

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

show abstract

An overview of lipid constituents in lipid nanoparticle mRNA delivery systems

Wu,

Lin,

Shi

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

AbstractmRNA therapeutics have shown great potential for a broad spectrum of disease treatment. However, the challenges of mRNA's inherent instability and difficulty in cellular entry have hindered its progress in the biomedical field. To address the cellular barriers and deliver mRNA to cells of interest, various delivery systems are designed. Among these, lipid nanoparticles (LNPs) stand out as the most extensively used mRNA delivery systems, particularly following the clinical approvals of corona virus disease 2019 (COVID‐19) mRNA vaccines. LNPs are comprised of ionizable cationic lipids, phospholipids, cholesterol, and polyethylene glycol derived lipids (PEG‐lipids). In this review, we primarily summarize the recent advancements of the LNP mRNA delivery technology, focusing on the structures of four lipid constituents and their biomedical applications. We delve into structure–activity relationships of the lipids, while also exploring the future prospects and challenges in developing more efficacious mRNA delivery systems.This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology‐Inspired Nanomaterials > Lipid‐Based Structures Nanotechnology Approaches to Biology > Nanoscale Systems in Biology

show abstract

A mathematical model with fractional-order dynamics for the combined treatment of metastatic colorectal cancer

Amilo,

Sadri,

Kaymakamzade

et al. 2024

Communications in Nonlinear Science and Numerical Simulation

View full text Add to dashboard Cite

Stage-specific treatment of colorectal cancer: A microRNA-nanocomposite approach

Cited by 4 publications

References 177 publications

UHPLC-HRMS-based Multiomics to Explore the Potential Mechanisms and Biomarkers for Colorectal Cancer

UHPLC-HRMS-based Multiomics to Explore the Potential Mechanisms and Biomarkers for Colorectal Cancer

An overview of lipid constituents in lipid nanoparticle mRNA delivery systems

A mathematical model with fractional-order dynamics for the combined treatment of metastatic colorectal cancer

Contact Info

Product

Resources

About